Clinical studies of the effectiveness oftargeted drugs (erlotinib, gefitinib, cetuximab), applied in combination withchemoradiation therapy against squamous-cell carcinoma of the head and neck with amutation in the EGFR gene, continue around the world. The gene discussed is EGFR; the disease is squamous cell carcinoma.